- Home
- TYRA vs RZLT Comparison
TYRA vs RZLT Comparison
Compare TYRA & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYRA
- RZLT
- Stock Information
- Founded
- TYRA 2018
- RZLT 2010
- Country
- TYRA United States
- RZLT United States
- Employees
- TYRA N/A
- RZLT N/A
- Industry
- TYRA Biotechnology: Pharmaceutical Preparations
- RZLT Biotechnology: Pharmaceutical Preparations
- Sector
- TYRA Health Care
- RZLT Health Care
- Exchange
- TYRA Nasdaq
- RZLT Nasdaq
- Market Cap
- TYRA 667.3M
- RZLT 626.4M
- IPO Year
- TYRA 2021
- RZLT N/A
- Fundamental
- Price
- TYRA $12.11
- RZLT $7.48
- Analyst Decision
- TYRA Strong Buy
- RZLT Strong Buy
- Analyst Count
- TYRA 8
- RZLT 5
- Target Price
- TYRA $31.00
- RZLT $12.50
- AVG Volume (30 Days)
- TYRA 243.4K
- RZLT 850.9K
- Earning Date
- TYRA 11-06-2025
- RZLT 11-06-2025
- Dividend Yield
- TYRA N/A
- RZLT N/A
- EPS Growth
- TYRA N/A
- RZLT N/A
- EPS
- TYRA N/A
- RZLT N/A
- Revenue
- TYRA N/A
- RZLT N/A
- Revenue This Year
- TYRA N/A
- RZLT N/A
- Revenue Next Year
- TYRA N/A
- RZLT N/A
- P/E Ratio
- TYRA N/A
- RZLT N/A
- Revenue Growth
- TYRA N/A
- RZLT N/A
- 52 Week Low
- TYRA $6.42
- RZLT $2.22
- 52 Week High
- TYRA $29.60
- RZLT $8.34
- Technical
- Relative Strength Index (RSI)
- TYRA 54.50
- RZLT 60.03
- Support Level
- TYRA $11.70
- RZLT $6.92
- Resistance Level
- TYRA $12.91
- RZLT $8.34
- Average True Range (ATR)
- TYRA 0.67
- RZLT 0.34
- MACD
- TYRA -0.04
- RZLT -0.03
- Stochastic Oscillator
- TYRA 30.38
- RZLT 39.58
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
About RZLT Rezolute Inc. (NV)
Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.